

SUPPORTING INFORMATION

Using carbon dioxide and calix[4]arenes to separate sodium


Hexiang Zhang and Dmitry M. Rudkevich*

*Department of Chemistry & Biochemistry, The University of Texas at
Arlington, Arlington, TX 76019-0065*

E-mail: rudkevich@uta.edu

General. Melting points were determined on a Mel-Temp apparatus (Laboratory Devices, Inc.) and are uncorrected. ^1H , ^{13}C NMR, COSY NMR spectra were recorded at 295 ± 1 K on JEOL 300 and 500 MHz spectrometers. Chemical shifts were measured relative to residual non-deuterated solvent resonances. FTIR spectra were recorded on a Bruker Vector 22 FTIR spectrometer. ESI-TOF high-resolution mass spectra were recorded on an Agilent ESI-TOF mass spectrometer at the Scripps Center for Mass Spectrometry (La Jolla, CA). Elemental analysis was performed on a Perkin-Elmer 2400 CHN analyzer. All experiments with moisture- and/or air-sensitive compounds were performed under a dried nitrogen atmosphere. All reagents were purchased from Sigma-Aldrich (St. Louis, MO) and AK Scientific (Mountain View, CA) used as received. Calixarenes **5**¹ and **6**² were prepared by known protocols.

S2




Scheme 1. Preparation of *t*-Bu calix[4]arene derivatives.

5,11,17,23-Tetra-*tert*-butyl-25,26,27,28-tetra-[BocHNC₂H₄NHC(O)CH₂O]-calix[4]-arene (7): *N*-Boc-ethylenediamine (0.24 mL, 1.5 mmol) and *t*-Bu-calix[4]arene tetraacid **6** (220 mg, 0.25 mmol) were mixed with EDC•HCl (191 mg, 1.0 mmol), HOBT (135 mg, 1.0 mmol) and NMM (0.1 mL) in dry CH_2Cl_2 (25 mL) and stirred at 0 °C overnight. The solution was evaporated to dryness. The solid was dissolved in CH_2Cl_2 (50 mL) and washed with 5% aq HCl (50 mL) and water (3 x 50 mL) and evaporated. The residue was recrystallized from MeOH to give tetraamide **7** as a white solid (259 mg, 62 %); m.p. > 240 °C (decomp); IR (KBr, cm^{-1}): ν 2964, 2880, 1692, 1534, 1480, 1392, 1365, 1251, 1174, 1126, 1043, 871; ^1H NMR (CDCl_3 , 500 MHz): δ 7.98 (br t, 4 H), 6.78 (s, 8 H), 5.49 (br, 4 H), 4.53 (d, J = 13.1 Hz, 4 H), 4.50 (s, 8 H), 3.50 (d, J = 5.1 Hz, 8 H), 3.29 (d, J = 5.1 Hz, 8 H), 3.24 (d, J = 13.1 Hz, 4 H), 1.43 (s, 36 H), 1.07 (s, 36 H); ^{13}C NMR (CDCl_3 , 500 MHz): δ 170.4, 156.6, 152.8, 146.0, 132.7, 126.0, 79.2, 74.3, 45.0, 40.8, 39.5, 34.0,

31.4, 28.5; ESI-TOF m/z 1449.8880, ($[M + H^+]$, calcd for $C_{80}H_{120}N_8O_{16}$ 1449.8895); Calcd for $C_{80}H_{120}N_8O_{16}$: C, 66.27; H, 8.34; N, 7.73. Found: C, 66.36; H, 8.17; N, 7.96.

5,11,17,23-Tetra-*tert*-butyl-25,26,27,28-tetra-[H₂NC₂H₄NHC(O)CH₂O]-calix[4]arene TFA salt (1 • 4TFA): Tetraamide **7** (145 mg, 0.1 mmol) and TFA (0.5 mL, 6.5 mmol) were dissolved in dry CH₂Cl₂ (10 mL) and stirred overnight. The solvent was removed, and Et₂O (20 mL) was added to precipitate tetraamine **1** as a TFA salt (129 mg, 86 %); m.p. 182-185 °C (decomp); IR (KBr, cm⁻¹): ν 2964, 2083, 1659, 1535, 1461, 1392, 1363, 1300, 1178, 1135, 1052, 872; ¹H NMR (DMSO-*d*₆, 300 MHz): δ 8.43 (br t, 4 H), 7.90 (br, 12 H), 6.81 (s, 8 H), 4.50 (d, $J = 12.9$ Hz, 4 H), 4.47 (s, 8 H), 3.40-3.38 (br q, 8 H), 3.20 (d, $J = 12.9$ Hz, 4 H), 2.90 (br, 8 H), 1.02 (s, 36 H); ¹³C NMR (DMSO-*d*₆, 300 MHz): δ 169.6, 159.0 (q, $J = 29.8$ Hz, CF₃C=O), 151.3, 146.8, 133.4, 126.1, 117.0 (q, $J = 295.2$ Hz, CF₃C=O), 74.4, 42.8, 41.8, 34.1, 31.6; ESI-TOF m/z 1049.6782, ([Free amine + H⁺], calcd for $C_{60}H_{89}N_8O_8$ 1449.6803); Calcd for $C_{68}H_{92}F_{12}N_8O_{16}$: C, 54.25; H, 6.16; N, 7.44. Found: C, 54.36; H, 6.17; N, 7.36.



Scheme 2. Reactions of *t*-Bu calix[4]arene tetraamine with CO_2 .

5,11,17,23-Tetra-*tert*-butyl-25,26,27,28-tetra- $[\text{H}_2\text{NC}_2\text{H}_4\text{NHC}(\text{O})\text{CH}_2\text{O}]$ -calix[4]arene carbamic acid (8): Compound **1•4TFA** (15 mg, 0.01 mmol) and TEA (0.02 mL) were dissolved in $\text{DMSO-}d_6$ (0.5 mL), after which CO_2 was then introduced to form carbamic acid **8**: ^1H NMR ($\text{DMSO-}d_6$, 300 MHz): δ 8.33 (br, 4 H), 6.81 (s, 8 H), 6.68 (br, 4 H), 4.52 (d, $J = 12.0$ Hz, 4 H), 4.46 (s, 8 H), 3.10 (d, $J = 12.0$ Hz, 4 H), 3.06 (br, 8 H), 1.04 (s, 36 H).

5,11,17,23-Tetra-*tert*-butyl-25,26,27,28-tetra- $[\text{H}_2\text{NC}_2\text{H}_4\text{NHC}(\text{O})\text{CH}_2\text{O}]$ -calix[4]arene carbamate (9): ^1H NMR ($\text{DMSO-}d_6$, 500 MHz): δ 8.50 (br t, 4 H), 6.85 (s + br s, 12 H), 6.80-6.00 (br), 4.55 (s, 8 H), 4.40 (d, $J = 12.4$ Hz, 4 H), 3.42 (m, 8 H), 3.21 (d, $J = 12.4$ Hz, 4 H), 2.90-2.85 (m, 24 H), 1.02 (m, 60 H). ^{13}C NMR ($\text{DMSO-}d_6$, 300 MHz): δ 170.5, 159.7 (q, $J = 30.5$ Hz, $\text{CF}_3\text{C}=\text{O}$), 153.3, 145.1, 133.5, 125.9, 117.5 (q, $J = 297.5$ Hz,

CF₃C=O), 74.4, 46.2, 37.6, 34.1, 31.6, 10.1. Due to the low concentration, the carbamate C=O singlet cannot be detected.³

Extraction of alkali-metal perchlorates (MClO₄) by calixarene (1); a general procedure: Compound **1** (15.0 mg, 0.01 mmol) was dissolved in 1 mL CHCl₃ in the presence of TEA (0.02 mL). Alkali-metal perchlorate (0.01 mmol) was added and the suspension was stirred overnight. The solution was separated. CO₂ (or ¹³CO₂) was then introduced and the precipitate was collected and dried. The ¹³C NMR spectrum of calixarene-Na⁺ carbamate polymer **3** was measured with ¹³CO₂ gas.



5,11,17,23-Tetra-*tert*-butyl-25,26,27,28-tetra-[H₂NC₂H₄NHC(O)CH₂O]-calix[4]arene NaClO₄ complex (2): ¹H NMR (DMSO-*d*₆, 300 MHz): δ 8.43 (br, 4 H), 7.12 (s, 8 H), 4.40 (s, 8 H), 4.34 (d, *J* = 12.0 Hz, 4 H), 3.40-3.37 (m, 8 H), 3.33 (d, *J* = 12.0 Hz, 4 H), 3.03-2.88 (br, 8 H), 1.12 (m, 36 H); ¹³C NMR (DMSO-*d*₆, 300 MHz): δ 170.6, 160.0 (q, *J* = 31.2 Hz, CF₃C=O), 151.8, 147.0, 134.3, 126.3, 117.6 (q, *J* = 295.2 Hz, CF₃C=O), 74.8, 46.2, 37.4, 34.4, 31.5, 30.6, 9.4.

5,11,17,23-Tetra-*tert*-butyl-25,26,27,28-tetra-[H₂NC₂H₄NHC(O)CH₂O]-calix[4]arene NaClO₄ complex carbamate (3): Obtained from **2** using ¹³C-labeled CO₂. ¹³C NMR (DMSO-*d*₆, 300 MHz): δ 170.5, 160.4 (¹³C=O), 159.7 (q, *J* = 31.6 Hz, CF₃C=O), 151.6, 147.0, 134.5, 126.3, 117.7 (q, *J* = 296.8 Hz, CF₃C=O), 74.9, 46.2, 37.8, 34.5, 31.5, 30.6, 10.1.



REFERENCES

- 1 M. A. McKerverey, E. M. Seward, G. Ferguson, B. Ruhl, S. J. Harris, *J. Chem. Soc., Chem. Commun.* 1985, **7**, 388.
- 2 A. Arduini, A. Pochini, S. Reverberi, R. Ungaro, *J. Chem. Soc., Chem. Commun.* 1984, 981.
- 3 (a) M. George, R. G. Weiss, *Langmuir* 2002, **18**, 7124. (b) M. George, R. G. Weiss, *Langmuir* 2003, **19**, 8168.



^1H NMR in $\text{DMSO}-d_6$ for compound **1**





^{13}C NMR in $\text{DMSO}-d_6$ for compound **1**





^1H NMR in $\text{DMSO-}d_6$ for compound **2**





^{13}C NMR in $\text{DMSO-}d_6$ for compound **2**




^1H NMR in $\text{DMSO-}d_6$ for compound **3**




^{13}C NMR in $\text{DMSO-}d_6$ for compound **3**





^1H NMR in CDCl_3 for compound **7**




S12





^{13}C NMR in CDCl_3 for compound **7**




S14





^1H NMR in $\text{DMSO-}d_6$ for compound **8**





S16




^1H NMR in $\text{DMSO-}d_6$ for compound **9**



^1H NMR in $\text{DMSO}-d_6$ for compound **1** with TEA




^1H NMR in $\text{DMSO-}d_6$ for compound **1** with KClO_4




+ TEA
+ KClO_4

4TFA




^1H NMR in $\text{DMSO-}d_6$ for compound **1** with CsClO_4




+ TEA

+ CsClO_4

4TFA



^1H NMR in CDCl_3 for solution after **2** was precipitated by CO_2



^1H NMR in CDCl_3 for compound **2**. $\text{KClO}_4/\text{NaClO}_4 = 1000$

